Peeling Back The Layers: Exploring Pfizer Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Pfizer (NYSE:PFE) has been analyzed by 17 analysts in the last three months, with a diverse range of perspectives. The average 12-month price target is $37.47, with a high of $75.00 and a low of $27.00, reflecting a 6.33% decline from the previous average. Recent actions by analysts show a trend of lowering price targets and maintaining or lowering ratings. Pfizer's financials indicate challenges with revenue growth, net margin, ROE, and ROA, but a positive aspect is its lower debt-to-equity ratio compared to the industry average.
January 04, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have lowered their price targets for Pfizer, indicating a bearish sentiment. The company faces revenue and profitability challenges, but has a positive debt-to-equity ratio.
The lowering of price targets by multiple analysts suggests a bearish outlook for Pfizer in the short term. The financial challenges highlighted in the article, such as declining revenue and below-average profitability metrics, could negatively impact investor sentiment. However, the company's lower reliance on debt financing is a positive factor that might mitigate some negative impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100